Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288260 | 0.84 | PTGS2 (0.45) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL3274519 | 0.72 | PTGS2 (0.40) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL2294327 | 0.71 | PTGS2 (0.44) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL16645128 | 0.70 | CA2 (0.51) | MAPTELANEADAMTS4 | |
| SCHEMBL16703079 | 0.69 | PTGS2 (0.48) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL2286233 | 0.68 | ELANE (0.34) | AKR1C3AKR1C2POLBMAPTELANE | |
| SCHEMBL3234259 | 0.68 | MMP2 (0.42) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL16702992 | 0.67 | CA2 (0.50) | PTGS2MMP2MMP9MMP14CYP11B1 | |
| SCHEMBL15967677 | 0.67 | ELANE (0.44) | ELANE | |
| SCHEMBL16702991 | 0.67 | PTGS2 (0.43) | PTGS2MMP2MMP9MMP14CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-7989641-B2 | Methods of synthesizing N-hydroxysuccinimidyl carbonates | XENOPORT, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | PTGS2 1669/4885MMP2 1502/4885MMP9 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.